Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials

Jonathan I. Silverberg, Eric L. Simpson, Emma Guttman-Yassky, Michael J. Cork, Marjolein De Bruin-Weller, Gil Yosipovitch, Laurent Eckert, Zhen Chen, Marius Ardeleanu, Brad Shumel, Thomas Hultsch, Ana B. Rossi, Jennifer D. Hamilton, Jamie M. Orengo, Marcella Ruddy, Neil M.H. Graham, Gianluca Pirozzi, Abhijit Gadkari

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background Pain is a frequent symptom of atopic dermatitis (AD). Objectives The aims of the study were to evaluate the effects of dupilumab on pain/discomfort in AD and to determine whether pain correlates with other outcomes. Methods This was a post hoc analysis of 5 randomized, placebo-controlled clinical trials in which adults with chronic AD received placebo or dupilumab 300 mg every 2 weeks or once weekly with and without topical corticosteroids. Proportions of patients with no pain/discomfort on this dimension of the 5-dimension EuroQoL (EQ-5D) at week 16 (all trials) and week 52 (CHRONOS) were compared between placebo and dupilumab. Correlations were evaluated between pain/discomfort and signs and symptoms of AD. Results Among 2632 evaluated patients, 72.9% to 83.1% reported at least moderate pain/discomfort at baseline. Higher proportions treated with dupilumab reported no pain/discomfort at week 16 relative to placebo; risk differences ranged from 22.3% (95% confidence interval = 11.5%-33.1%) to 42.2% (95% confidence interval = 26.6%-57.8%, all P ≤ 0.0001), with similar effects observed at week 52. Correlations at baseline of pain/discomfort with signs and symptoms of AD were low to moderate. Conclusions Pain/discomfort, present in a substantial proportion of patients with moderate-to-severe AD, was significantly reduced by dupilumab treatment. Given the low-to-moderate correlations with other AD symptoms at baseline, pain likely represents a distinct AD symptom. Trial Registration: ClinicalTrials.gov identifiers NCT01859988, NCT02277743, NCT02277769, NCT02260986, and NCT02755649.

Original languageEnglish (US)
Pages (from-to)S81-S91
Issue number1
StatePublished - Oct 1 2021

ASJC Scopus subject areas

  • Immunology and Allergy
  • Dermatology


Dive into the research topics of 'Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials'. Together they form a unique fingerprint.

Cite this